Acambis signs JE partnership agreement with sanofi pasteur
Acambis plc announced a partnership agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group, for ChimeriVax(TM)-JE, Acambis' single-dose vaccine against Japanese encephalitis (JE).
Under the agreement, Acambis has granted sanofi pasteur marketing, distribution and certain manufacturing rights to ChimeriVax-JE worldwide, excluding India and the Indian subcontinent where Acambis has an existing agreement with Bharat Biotech International Limited, and also excluding the US, for which sanofi pasteur has been granted an option. Sanofi pasteur plans to introduce the new vaccine in Europe and throughout the Asia Pacific region, with particular focus on the large endemic countries, including Thailand and China.
Acambis will receive royalties on sales and payment for the supply of bulk manufactured ChimeriVax-JE product. In addition, it will receive upfront and milestone payments of up to EUR30 million (c. £20m) following marketing authorisation of ChimeriVax-JE in key endemic countries and in the European Union. Acambis has already established a large-scale manufacturing process at its facility in Canton, MA, US, from which it will supply sanofi pasteur with bulk ChimeriVax-JE vaccine.
Other news from the department research and development
